| Scorecard |
|---|
|
4 / 5 Stars
|
|
Lipper
---
|
|
Zacks Investment Research
---
|
|
Standard & Poor's
---
|
|
TheStreet.com
A+
(Buy)
|
Fund Holdings
Asset Allocation
| % Long | % Short | % Net | |
|---|---|---|---|
| Cash | 3.48 | 0.0 | 3.48 |
| Stocks | 76.25 | 0.0 | 76.24 |
| Bonds | 0.0 | 0.0 | 0.0 |
| Other | 0.23 | 0.52 | -0.3 |
| Foreign Bonds | 0.23 | 0.0 | 0.23 |
| Foreign Stocks | 20.29 | 0.0 | 20.29 |
| Convertible | 0.06 | 0.0 | 0.06 |
| Preferred | 0.0 | 0.0 | 0.0 |
Updated 02.28.2013
Top 10 Holdings
Performance as of 04.30.2013
Portfolio as of 02.28.2013
| Ticker | YTD Return % | % Net Assets | |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | ALXN | 3.13 | 4.93 |
| Catamaran Corp | CTRX | 21.04 | 4.61 |
| Gilead Sciences Inc | GILD | 36.53 | 4.3 |
| Pharmacyclics, Inc. | PCYC | 31.97 | 3.24 |
| Valeant Pharmaceuticals International Inc | VRX | 23.29 | 2.87 |
| Incyte Corp Ltd | INCY | 29.56 | 2.04 |
| UnitedHealth Group Inc | UNH | 10.5 | 1.95 |
| Regeneron Pharmaceuticals, Inc. | REGN | 38.71 | 1.69 |
| McKesson, Inc. | MCK | 9.27 | 1.61 |
| Celgene Corporation | CELG | 48.67 | 1.6 |
